https://allsci.com/news/licensing-and-partnerships/glaukos-ro-104-licenses-preclinical-tri-specific/ AllScien 2026-10-09T11:44:02.656427Z Glaukos licenses preclinical tri-specific retinal biologic RO-104 from RevOpsis https://allsci.com/news/biotech/thyroid-eye-disease-sycume-teprotumumab-n01-meets/ AllScien 2026-10-09T11:26:24.238159Z Innovent's Sycume hits Phase III endpoint in Chinese thyroid eye disease trial https://allsci.com/news/clinical-trials/optogenetic-therapy-for-advanced-retinitis/ AllScien 2026-10-09T11:10:41.447210Z GenSight's optogenetic gene therapy restores limited visual function in Phase I/II blindness trial https://allsci.com/news/approvals/dmmr-colon-cancer-fda-approves-tecentriq-as/ AllScien 2026-10-09T11:10:13.311918Z Roche's Tecentriq wins 12th FDA indication, for stage III colon cancer https://allsci.com/news/clinical-trials/ruvonoflast-semaglutide-rezeras-shows-favorable/ AllScien 2026-10-09T09:35:03.207236Z Rezera's ruvonoflast boosts semaglutide's anti-inflammatory effects in Phase II trial https://allsci.com/news/biotech/parkinsons-dyskinesia-mentara-therapeutics/ AllScien 2026-10-09T09:25:57.481357Z Mentara launches in Oz with PDE10A inhibitor for Parkinson's dyskinesia, targets Phase II in 2027